GeneDx has appointed Linda Genen, MD, MPH as Chief Medical Officer to lead its Medical and Clinical Affairs division and accelerate the integration of genomic medicine into routine care. Dr. Genen brings over two decades of clinical and payer strategy experience, including her tenure as CMO at ProgenyHealth and senior roles at UnitedHealth Group and Optum. She will partner with GeneDx’s innovation, commercial and policy teams to shape real-world evidence initiatives, guide payer engagement and champion adoption of exome and genome testing across health systems. CEO Katherine Stueland highlighted Dr. Genen’s track record in maternal-infant health and digital care delivery, noting her leadership will help reduce disease progression, improve outcomes and lower costs by delivering genomic insights earlier in the patient journey.

In 2025 GeneDx published 79 peer-reviewed studies, bringing its total to over 1,100 publications powered by GeneDx Infinity™, the largest rare disease genomic dataset with nearly one million exomes and genomes. Key accomplishments included four practice-shaping manuscripts, 56 GeneMatcher discoveries and 38 abstracts at major scientific conferences. The GUARDIAN newborn screening study was named in JAMA’s Research of the Year Roundup for demonstrating broader actionable condition detection than traditional screening. SeqFirst Neo and SeqFirst Floor publications established rapid genome sequencing for critically ill newborns and non-critical pediatric wards, while a Q4 study confirmed exome sequencing’s superiority over panel testing for seizure indications. These efforts resulted in 31 newly validated gene–disease associations in 2025 and diagnoses for 136 patients through collaborations with 175 clinicians at 74 institutions, reinforcing GeneDx’s leadership in translating genomic discovery into clinical practice.